期刊
EXPERIMENTAL CELL RESEARCH
卷 316, 期 1, 页码 1-11出版社
ELSEVIER INC
DOI: 10.1016/j.yexcr.2009.10.012
关键词
Osteopontin; Akt; beta-Catenin; TCF/LEF; ILK; PI3-kinase
资金
- National Institute of Health [AR46292, DE18308, F30, DE07309]
- Department of Biomedical Sciences, Dental School, University of Maryland, Baltimore [T32]
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046292, R56AR046292] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE007309] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F30DE018308] Funding Source: NIH RePORTER
Secretion of osteopontin (OPN) by cancer cells is a known mediator of tumorigenesis and cancer progression in both experimental and clinical studies. Our work demonstrates that OPN can activate Akt, ail important step in cancer progression. Both ILK and PI3K are integral proteins in the OPN/Akt pathway, as inhibition of either kinase leads to a loss of OPN-mediated Akt activation. Subsequent to OPN-induced Akt activation, we observe inactivation of GSK-3 beta, a regulator of beta-catenin. Osteopontin stimulation leads to an overall increase in beta-catenin protein levels with a resultant transfer of beta-catenin to the nucleus. Through the nuclear import of beta-catenin, OPN increases both the transcription and protein levels of MMP-7 and CD44, which are known TCF/LEF transcription targets. This work describes an important aspect of cancer progression induced by OPN. (C) 2009 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据